ENGAGING STAKEHOLDERS, FORMING STRATEGIC TECHNOLOGY PARTNERSHIPS AND TESTING SOLUTIONS INCREMENTALLY WILL ALSO BE ESSENTIAL TO SUPPORTING A POSITIVE TRANSITION.
D I G I T A L D I A G N O S T I C S with real-time summaries of relevant guidelines, emerging therapies and complex clinical protocols. Gen AI models can distill huge volumes of literature, highlight dedicated treatments for rare diseases, and identify medication programmes tailored to the patient’ s genomic and clinical profile.
2. Prognostic modelling and specialistlevel insights. Advanced AI models can forecast patient trajectories, aiding consultants in predicting adverse events, gauging treatment efficacy and planning long-term care. In cardiology, for instance, AI algorithms can preempt arrhythmic episodes or detect orthostatic hypotension risk factors, preventing dizziness-related falls. A notable example is FPT’ s eCarePlus, an AI-powered solution that analyses ECG and patient activity data to detect early signs of syncope and fall risks. This proactive system enables timely interventions that improve patient safety and reduce complications from falls.
3. Streamlining administrative burdens. AI tools can handle extensive documentation, from synthesising patient history into concise notes to summarising regulatory guidelines. This allows consultants to devote more time to complex decision-making and direct patient interaction. One such innovation is FPT’ s AI Scribe, a generative AI-powered Speech-to- Text solution that transcribes spoken medical information into structured electronic health records( EHRs), fully compliant with HL7 FHI7, the global next-generation interoperability standard created by the standards development organisation Health Level 7. By automating documentation, AI Scribe frees up consultants to focus on complex decision-making and direct patient care, while ensuring compliance and data accessibility across the clinical workflow.
4. Next-generation care for rare and complex therapies. AI systems can continuously monitor research, clinical trials and guidelines, alerting consultants to breakthrough treatments. These systems can highlight newly approved biologics for rare bone
ENGAGING STAKEHOLDERS, FORMING STRATEGIC TECHNOLOGY PARTNERSHIPS AND TESTING SOLUTIONS INCREMENTALLY WILL ALSO BE ESSENTIAL TO SUPPORTING A POSITIVE TRANSITION.
disorders and integrate personalised genomic data( including genes and DNA) for targeted therapies.
5. Patient engagement and communication. Generative AI can produce patient-specific educational materials, simplifying treatment plans and increasing adherence. Chatbots handle routine queries and appointment reminders, allowing staff to focus on complex patient needs.
Considerations for ethical and successful AI
Employing trustworthy AI means adhering to ethical and regulatory considerations, such as the UK GDPR and Data Protection Act 2018. Transparent algorithms and interpretability features are important to maintain clinician trust and auditable decision-making paths will ensure that AI’ s role remains advisory and accountable.
Human supervision and validation by consultants are essential to ensure system performance is enhanced over time. As consultants remain central to clinical judgment, AI recommendations must be validated and, when appropriate, challenged by human expertise. Continuous feedback loops, where clinicians endorse or reject AI suggestions, will ensure AI is optimised for the best patient care outcomes.
Successful adoption relies on clinician training to be able to effectively interpret AI outputs, manage device interfaces and discuss AI-guided recommendations with patients. Engaging stakeholders, forming strategic technology partnerships and testing solutions incrementally will also be essential to supporting a positive transition. �
www. intelligenthealth. tech 65